Innoviva (INVA) Specialty Therapeutics, a subsidiary of Innoviva, announced the United States commercial availability of ZEVTERA, the newest addition to the company’s growing antibiotic portfolio. ZEVTERA is the only U.S. FDA approved advanced-generation cephalosporin indicated to treat adult patients with Staphylococcus aureus bloodstream infection, including those with right-side endocarditis caused by methicillin-susceptible and methicillin-resistant isolates. ZEVTERA is the latest approved MRSA SAB therapy since 2006.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INVA: